IFRX (InflaRx NV) Debt-to-Equity : 0.01 (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Debt-to-Equity?

InflaRx NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.44 Mil. InflaRx NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $0.55 Mil. InflaRx NV's Total Stockholders Equity for the quarter that ended in Sep. 2024 was $72.46 Mil. InflaRx NV's debt to equity for the quarter that ended in Sep. 2024 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for InflaRx NV's Debt-to-Equity or its related term are showing as below:

IFRX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0 Med: 0.01 Max: 0.02
Current: 0.01

During the past 9 years, the highest Debt-to-Equity Ratio of InflaRx NV was 0.02. The lowest was 0.00. And the median was 0.01.

IFRX's Debt-to-Equity is ranked better than
99.9% of 1025 companies
in the Biotechnology industry
Industry Median: 0.14 vs IFRX: 0.01

InflaRx NV Debt-to-Equity Historical Data

The historical data trend for InflaRx NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Debt-to-Equity Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.01

0.02

0.01

InflaRx NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Competitive Comparison of InflaRx NV's Debt-to-Equity

For the Biotechnology subindustry, InflaRx NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Debt-to-Equity falls into.

InflaRx NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

InflaRx NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.408	+	0.814)	/	111.867
	=	0.01

InflaRx NV's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.443	+	0.554)	/	72.455
	=	0.01

InflaRx NV (NAS:IFRX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

InflaRx NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.